South Korean RNAi-based drug developer plans U.S. expansion, 10 new clinical programs, and a pandemic vaccine
OliX Pharmaceuticals, a South Korean developer of RNAi therapeutics plans to expand its U.S. operations and advance up to 10 programs into clinical trials over the next three years—nearly doubling the size of its pipeline—toward its vision of becoming a top-three company in nucleic acid therapeutics. [OliX Pharmaceuticals]
OliX says its expansion will include the construction of an RNA synthesis GMP manufacturing facility at its San Diego site, which will initially carry out oligonucleotide chemistry and analysis for investigational therapeutics to be developed in-house for clinical testing, with the potential to manufacture commercial RNAi therapeutics there . . .
